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ABSTRACT 
This article reviews clinically relevant data regarding punctate inner choroidopathy, mainly the various treatment 
options. Punctate inner choroidopathy is an uncommon, inflammatory, multifocal chorioretinopathy affecting mostly 
young myopic women. It is characterized by the presence of multiple, small, well-defined, yellow-white fundus lesions, in 
the absence of intraocular inflammation. We describe etiology, clinical findings and ancillary tests that help in the 
diagnosis and detection of complications. Treatment options that have been used to manage patients with PIC and CNV 
include immunosuppressants, corticoids, laser photocoagulation, photodynamic therapy, intravitreal anti-VEGF agents 
and submacular surgery. 
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INTRODUCTION 
The term punctate inner choroidopathy (PIC) was first 
used by Watzke, et al. (1) in 1984, to describe findings in 
a group of myopic patients with multifocal, well-
circumscribed, small choroidal lesions after an infectious 
cause has been ruled out. 
PIC is an infrequent ocular inflammatory disease, 
frequently affecting young myopic women. Patients 
present symptoms of loss of central visual acuity (VA), 
photopsia and scotomata. On fundoscopy, there are 
multiple, small, round, yellowish-white punctate lesions, 
in the absence of signs of intraocular inflammation (1, 2). 
Spectral domain optical coherence tomography (SD-OCT) 
provides structural characteristics of PIC lesions (3). On 
fluorescein angiography (FA), the lesions fill and stain 
during the late phase. Autofluorescence (AF) images 
show hypofluorescence in cicatricial lesions and 
autofluorescence in active lesions (2). 
PIC is usually a benign disease; however, severe visual 
loss can occur if complicated by choroidal 
neovascularization (CNV) and subretinal fibrosis (3). 




This systematic review describes PIC, using pertinent 
evidence available in the literature about epidemiology, 
clinical findings, ancillary tests, clinical course, 
complications and treatment. 
Studies were identified by searching the electronic 
literature (Pubmed/MEDLINE) for reports published 
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between 1984 and 2014, using the terms “punctate inner 
choroidopathy”, “choroidal neovascularization”, 
combined with “treatment”, “anti-VEGF agents” “optical 
coherence tomography”, “fluorescein angiography”, 
“indocyanine green angiography”. 
Review articles and case reports were included. We also 
manually searched the reference lists of identified 
studies. Studies were assessed independently by two of 
the authors (JC and SM) and were not limited by 
language or country. 
 
ETIOLOGY 
The underlying pathophysiology and etiology of the 
disorder are not entirely understood. Jampol, et al. (13) 
proposed that there is a familiar predisposition to 
autoimmune/inflammatory diseases, which leads to a 
response against antigens in the outer retina and inner 
choroid, triggered by an unknown agent. This process 
seems to be analogous to presumed ocular 
histoplasmosis syndrome (POHS), but further studies are 
required to analyze the genetic and environmental 
factors that contribute to the development of the 
disease. Some authors defend that PIC may be an 
independent inflammatory disease, while others suggest 
that it may be part of a spectrum of entities known as 
White Spot Syndromes of the Retina (13).  
Hirooka, et al. (14) quantified choroidal blood flow 
velocity at the macula using laser speckle flowgraphy in a 
patient with PIC treated with systemic corticosteroids. 
Choroidal blood flow decreased and choroidal thickness 
increased during the acute phase of PIC. Their results 
suggested that changes in the choroidal circulation 
related to inflammation may contribute to the 
pathogenesis of PIC and might involve a wider area in the 
posterior pole than the area of the PIC lesion. 
 
CLINICAL FINDINGS 
In a recent study (15), 93% of 136 patients diagnosed 
with PIC were women, with a mean age at the initial visit 
of 32 years (range from 16 to 64) and mean spherical 
equivalent refraction of -4.6 diopters. The most common 
symptoms reported were photopsia and blurred vision. 
Gerstenblit, et al. (4) evaluated the demographic and 
clinical features of a sample of 77 persons with PIC. Of 
these, 90% were women and 85%were myopic. The 
median age was 30 years (range from 15 to 55). The most 
frequent symptom was scotomata in 91%. Other 
common symptoms were: blurred vision (86%), 
photopsia (73%), floaters (69%), photophobia (69%), 
metamorphopsia (65%), and loss of peripheral vision 
(26%).  
Essex, et al. (15) found that, at the initial visit, 47% of 
patients had unilateral disease and 53% had bilateral 
disease at baseline, 23% having uncomplicated disease 
and 77% presenting CNV. On the other hand, Brown, et 
al. (16) reported bilateral disease in 88% of patients with 
PIC. Considering VA loss, Essex, et al. (15) described a 
mean final VA of 5/10 or better in 178 eyes (66%) and 
less than 1/10 in 41 eyes (15%). The reason for loss of 
vision was recognized in 138 eyes: 119 eyes had CNV, 17 
eyes had PIC lesions in the absence of CNV and 2 eyes 
had epiretinal membrane. Brown, et al. (16) studied a 
group of 30 eyes (16 patients), with a mean follow of 51 
months. They found a mean VA of 5/10 or better in 77% 
(23 eyes) and 4/10 or worse in 23% (7 eyes), with 6 of 
these 7 eyes 1/10 or worse. Severe visual loss was mainly 
due to subfoveal CNV and fibrosis. 
In our case report (17), anatomical improvement was 
achieved after treatment of CNV with intravitreal anti-
VEGF, but there wasn’t prompt restoration of VA. There 
was a considerable improvement of VA one year after 
treatment, with a final VA of 5/10. 
Biomicroscopy is characterized by the absence of ocular 
inflammation (vitritis, pars planitis, anterior chamber 
cells or anterior synechiae). Fundus examination reveals 
multiple, small (ranging from 100 to 300 μm in diameter), 
white or yellow, opaque round lesions, spread through 
the posterior pole or occasionally in a linear pattern (1). 
These lesions appear to be located at the level of the 
choroid and the retinal pigment epithelium (RPE) and can 
sometimes coalesce and form a serous retinal 
detachment (1, 3). 
PIC is usually a benign disease, with favorable visual 
prognosis (5) and resolution of acute lesions in a few 
weeks. It frequently progress into atrophic chorioretinal 
scars. These scars can become pigmented after a few 
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COMPLICATIONS 
CNV and subretinal fibrosis are the most common and 
visual-threatening complications in PIC: rates of up to 
69% and 56%, respectively, were reported in a series of 
77 patients (4). In a smaller series of 12 patients, 75% 
had CNV (19). 
The presence of lesions in the fellow eye of patients with 
unilateral PIC complicated with CNV seems to be a risk 
factor for development of CNV (15). 
ANCILLARY TESTS 
Optical Coherence Tomography (OCT) 
Channa, et al. (3) studied retinal changes on SD-OCT 
associated with PIC lesions. They found that the majority 
of the lesions (89%), regardless of clinical activity, 
presented involvement of the RPE, such as RPE elevation 
with sub-RPE signals and RPE discontinuity, overlying an 
apparently intact Bruch’s membrane. 
Zarranz-Ventura, et al. (20) characterized a total of 90 PIC 
lesions, where 46.6% of them consisted of focal atrophy 
of the outer retina and RPE, 34.4% of sub-RPE 
hyperreflective deposits and 18.8% of focal RPE 
elevations with underlying hyporreflective space. It was 
suggested that this focal RPE elevation is seen in active 
phases, progressing later to focal atrophy of outer retinal 
layers or to sub-RPE hyperreflective deposits. Overall, SD-
OCT can provide structural characteristics of PIC lesions, 
as well as information not detected clinically, such as 
early identification of recurrence of disease activity (3). 
However, SD-OCT does not permit a detailed study about 
the extent of choroidal involvement (3).Enhanced depth 
imaging (EDI) technique can be used to study the 
choroid. Recently reports (14, 20) described its use in 
patients with PIC and found that choroidal thickness 
increases during the acute phase and decreases with 
regression of PIC. The use of OCT in PIC is also useful in 
the evaluation of treatment response in patients with 
CNV (20). 
Fluorescein Angiography 
Watzke, et al. (1) described that PIC lesions are 
hyperfluorescent in the early arterial phase, with staining 
in the arteriovenous phase. Olsen, et al. (5) studied5 
patients (6 eyes) with CNV secondary to PIC and 
described their FA findings. CNV appeared as focal areas 
with an irregular, lacy network of neovascularization, 
with hyperfluorescence in the early phase and leakage in 
the late phase. With time, the new vessels formed a 
larger neovascular complex. 
Indocyanine Green Angiography 
Indocyanine green angiography (ICGA) findings show that 
PIC affects choriocapillaris and inner choroid (21). This 
exam shows mainly hypofluorescence in the early, 
middle and late phases, which probably corresponds to 
choroidal hypoperfusion. Tiffin, et al. (21) also described 
localized points of hyperfluorescence on the vessel walls 




Punctate inner choroidopathy is a relatively uncommon 
condition, with small published case series, so some 
features of the disease are not yet completely 
understood. The choice of the treatment for the PIC and 
CNV secondary to PIC has been limited by this lack of 
information. Many patients with PIC and no evidence of 
CNV do not need treatment, as the visual prognosis is 
good. However, treatment may be considered for those 
with inflammatory lesions (but no CNV) very close to 
fixation (18). 
Recently, most research has been targeted at preventing 
visual impairment caused by the development of CNV. In 
one study, Gerstenblith, et al. (4) reported data from 77 
patients diagnosed with PIC who were surveyed by the 
PIC Society. From those, 86% told they had received 
treatment: 60% with systemic corticosteroids, 22% with 
intraocular corticosteroids and 10% with periocular 
corticosteroids. In addition, approximately 14% reported 
treatment with at least one other immunosuppressive 
drug (mycophenolate mofetil, cyclosporine, 
methotrexate and azathioprine) during the course of the 
disease. Thirty-eight survey participants (49%) reported 
having received laser treatment (including PDT) (4). 
Corticosteroids 
Some authors have reported the use of systemic or 
periocular/intraocular steroids in PIC and in PIC-
associated CNV (8, 22, 23). Levy, et al. (8) reported a case 
of a patient with juxtafoveal CNV due to PIC treated with 
oral corticosteroids. VA improved in 1 week, from 1/10 
to 6.7/10, following treatment with oral prednisone 60 
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mg/day gradually tapered. Authors advocated that, 
although resolution of the PIC lesions may occur 
spontaneously, oral steroids help achieve more rapid 
recovery of VA. They also defend that steroids maybe 
used in cases with active CNV since they promote a 
reduction of the inflammatory and endothelial 
proliferative mechanisms. 
Flaxel, et al. (22) used oral corticosteroids in patients 
with subfoveal CNV and PIC with visual symptoms, with 
good visual and anatomic outcome. The patients 
underwent a course of 1 mg/kg per day of oral 
prednisolone for 3-5 days, then tapered over 6-8 weeks. 
In this paper, they defended that oral systemic 
corticosteroids is a good option for healthy young 
patients with active subfoveal CNV secondary to PIC. 
However, there are some systemic and local adverse 
effects of corticosteroids that could justify avoiding this 
treatment in some patients (5). 
Immunomodulators 
Turkcuoglu, et al. (7) treated 8 patients with PIC, who 
had at least 2 recurrent episodes of increased activity, 
with mycophenolate mofetil. Authors concluded that this 
immunomodulatory therapy decreased frequency of 
attacks in recurrent PIC. 
Intravitreal Anti-VEGF 
In the last years, several studies have been published 
considering the use of intravitreal anti-VEGF for treating 
CNV in PIC (Table 1). 
Chan, et al. (12) reported 4 cases of CNV due to PIC 
treated with 3 monthly injections of intravitreal 
bevacizumab. After 6 months of follow-up, all patients 
improved and none had VA worse than 5/10. All cases 
showed no angiographic leakage at months 3 and 6. In 
2010, Leung, et al. (24) reported a case of PIC 
complicated by CNV treated with a single injection of 
intravitreal ranibizumab. There was improvement in VA, 
with no recurrence of disease activity at 8 months. 
Menezo, et al. (25) described results of 10 patients with 
CNV secondary to PIC which were treated with 
intravitreal ranibizumab (average of 1.9 injections). 
Previous therapies included PDT, sub-tenon 
triamcinolone, oral prednisolone and intravitreal 
triamcinolone. Nine eyes maintained or improved vision, 
after treatment. No ocular or systemic complications 
were observed. 
Mangat, et al. (11) described successful cases of 4 
patients with CNV secondary to PIC treated solely with 
anti-VEGF in 3 cases and in combination with PDT in the 
other. Authors proposed that anti-VEGF should be the 
first line of treatment due to good results without serious 
complications, although frequent follow-up for a long 
period is recommended to detect recurrences. They also 
emphasized that some patients with PIC-related CNV 
may be less responsive to anti-VEGF, requiring other 
treatment options. 
Rouvas, et al. (26) evaluated the effect of intravitreal 
injections of ranibizumab on VA and central foveal 
thickness in 15 patients with CNV associated with various 
ocular inflammatory clinical entities, 5 of them with PIC. 
Repeated intravitreal injections were performed when 
persistent or recurrent fluid on OCT and/or signs of 
active CNV on angiography were present. The mean 
follow-up time was 70.4 ± 24 weeks. Their study supports 
the promising results of intravitreal ranibizumab in VA 
improvement and decrease in macular thickness in 
patients with inflammatory CNV. 
Zhang, et al. (27) evaluated the efficacy and safety of 
intravitreal bevacizumab as primary treatment of CNV 
secondary to PIC in 12 patients (12 eyes). All eyes had 
stable or improved vision. Mean best-corrected VA 
improved from 3.2/10at baseline to 5.9/10 at 12 months 
of follow-up. Mean central retinal thickness decreased 
from 333 μm to 241 μm. No systemic or ocular side 
effects were observed. 
We published, in 2013, a case report of a 29-year-old 
caucasian male with PIC complicated by CNV (17). A 
single intravitreal injection of bevacizumab 1.25 mg/0.05 
ml was given, with anatomic and visual improvement. 
Even though some authors used 3 monthly injections of 
anti-VEGF (12, 28), we treated with only 1 injection and 
the patient showed no need of additional doses. There 
was no recurrence after 2 years of follow up. 
In 2014, Jiménez, et al. (28) reported a case report of a 
female patient with CNV due to PIC, treated with 
intravitreal injections of ranibizumab in a monthly 
administration up to 3 injections. One month after the 
third injection, VA reached 10/10 and OCT revealed no 
intra nor subretinalfluid. There was no recurrence during 
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Table 1. Studies Considering the Use of Intravitreal Anti-VEGF for Treating CNV in PIC 
IVT = Intravitreal 
 
Laser Photocoagulation 
Brown, et al. (16) reported 2 cases with extrafoveal CNV 
due to PIC, treated with laser photocoagulation. Both 
patients had final VA of 5/10 or better, but initial VA was 
not stated in the paper. 
There is an increased risk of developing CNV after argon 
laser due to aggression and rupture of the Bruch’s 
membrane. Additionally, laser scars enlarge with time 
and the fovea may be later involved. 
Photodynamic Therapy 
Postelmans, et al. (29) analyzed cases of 7 patients (7 
eyes) treated only with PDT. Mean VA increased from 
4.5/10 to 7.5/10, after a mean follow-up of 22 months 
and a mean number of 2.5 (range from 1 to 4) PDT 
sessions. VA remained stable or improved in 6 of the 7 
eyes and decreased in only1 eye. No serious systemic or 
ocular side effects related to PDT were observed. 
Coco, et al. (30) performed a retrospective analysis of 8 
patients (8 eyes) with PIC treated with PDT (mean of 3.3 
treatments per patient), followed for a mean of 22.7 
months. They concluded that PIC seems to have 
relatively higher rates of CNV recurrence after PDT 
compared to other inflammatory or idiopathic diseases; 
however, this rate seems to be lower than that after 
submacular surgery (5). In this study, 2 patients suffered 
CNV recurrences more than15 months after initial PDT 
treatment and required additional PDT sessions. In this 
way, authors hypothesized that there is a trend for CNV 
in PIC to recur a long time after PDT treatment. 
Brouzas, et al. (6) reported on along-term follow-up 
study (average of 105 months) CNV cases secondary to 
PIC: 4 patients (4 eyes) treated with PDT and4 patients (5 
eyes) left without treatment. Improvement of VA was 
observed in 6 eyes, including all the treated eyes and 2 of 
the 5 untreated eyes. The size of the lesions, including 
CNV and subretinal fibrosis, increased in all cases left 
untreated and remained stable in all cases treated with 
PDT. The authors concluded that, even though the 
untreated CNV due to PIC is slowly progressive, 
treatment with PDT appears to help in maintaining VA 
and stabilizing the progression of CNV and fibrosis. 
Submacular Surgery 
In 1996, Olsen, et al. (5) reported 5 patients (6 eyes) with 
PIC and subfoveal CNV treated with submacular surgery. 
Every patient improved VA after surgery. The mean 
follow-up was 14 months. Nevertheless, recurrences 
were common (66.7%) and resulted in a significant 
decrease of VA. They concluded that submacular surgery 
may be a successful treatment for the CNV associated 
with PIC in selected patients, depending on the timing 
and location of CNV (they did not recommend surgical 
Author Year N (Patients) N (Eyes) Treatment Dose 
Chan, et al. (12) 2007 4 4 Bevacizumab 1.25 mg/0.05 ml 
Leung, et al. (24) 2010 1 1 Ranibizumab 0.5 mg/0.1 ml 
Menezo, et al.(25) 2010 10 10 Ranibizumab 0.5 mg/0.1 ml 
Mangat, et al. (11) 2011 4 4 Ranibizumab/Bevacizumab 0.5 mg/0.1 ml / 1.25 mg/0.05 ml 
Rouvas, et al. (26) 2011 5 5  Ranibizumab 0.5 mg/0.1 ml 
Zhang, et al. (27) 2012 12 12 Bevacizumab 1.25 mg/0.05 ml 
Campos, et al. (17) 2013 1 1 Bevacizumab 1.25 mg/0.05 ml 
Jiménez, et al. (28) 2014 1 1 Ranibizumab 0.5 mg/0.1 ml 
 
 
Med Hypothesis Discov Innov Ophthalmol. 2014; 3(3)  
 
81 PUNCTATE INNER CHOROIDOPATHY 
treatment of extrafoveal CNV). The high rate of 
recurrence observed and the additional costs and risks of 
surgery can also influence the treatment choice. 
 
CONCLUSION 
PIC is an inflammatory disease affecting choroid and RPE. 
In general, the prognosis is good and some cases do not 
need treatment. Nevertheless, there are severe cases, 
complicated with CNV, that require treatment and can 
lead to visual impairment. 
There is a lack of studies with a large number of patients 
that might clarify the cause, precipitating factors and 
pathophysiology. This information would be useful to 
define the more appropriate treatment. 
Intravitreal anti-VEGF treatment appears to be a good 
choice as the first line of treatment in CNV secondary to 
PIC. However, there is a need for further prospective 
studies with larger samples to confirm safety, efficacy 
and the best treatment regimen. 
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